Organogenesis (NASDAQ:ORGO) Raised to Sell at Wall Street Zen

Organogenesis (NASDAQ:ORGO) was upgraded by stock analysts at Wall Street Zen from a “strong sell” rating to a “sell” rating in a research report issued on Saturday, Wall Street Zen reports.

Several other equities analysts have also weighed in on the stock. UBS Group set a $3.00 price objective on shares of Organogenesis in a research report on Thursday, May 28th. Truist Financial dropped their target price on shares of Organogenesis from $3.00 to $2.00 and set a “hold” rating on the stock in a report on Friday, August 7th. Finally, Weiss Ratings cut shares of Organogenesis from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, September 4th. Two analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Reduce” and an average target price of $4.33.

Organogenesis Price Performance

ORGO opened at $1.42 on Friday. The company has a debt-to-equity ratio of 0.07, a quick ratio of 3.00 and a current ratio of 3.52. The company has a market capitalization of $182.73 million, a PE ratio of -1.65 and a beta of 1.29. The stock’s fifty day moving average is $1.98 and its 200-day moving average is $2.30. Organogenesis has a one year low of $1.34 and a one year high of $7.08.

Organogenesis (NASDAQ:ORGO) last announced its earnings results on Thursday, August 6th. The company reported ($0.71) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.36). Organogenesis had a negative net margin of 19.94% and a negative return on equity of 23.89%. The firm had revenue of $43.76 million for the quarter, compared to the consensus estimate of $54.27 million.

Hedge Funds Weigh In On Organogenesis

Several institutional investors and hedge funds have recently bought and sold shares of ORGO. BlackRock Inc. acquired a new position in Organogenesis during the second quarter worth $17,616,000. Dimensional Fund Advisors LP lifted its position in shares of Organogenesis by 5.9% in the first quarter. Dimensional Fund Advisors LP now owns 2,891,006 shares of the company’s stock worth $6,851,000 after buying an additional 160,026 shares during the last quarter. Deutsche Bank AG acquired a new stake in shares of Organogenesis in the second quarter worth about $4,146,000. Renaissance Technologies LLC boosted its stake in shares of Organogenesis by 30.5% during the 1st quarter. Renaissance Technologies LLC now owns 1,068,538 shares of the company’s stock worth $2,532,000 after acquiring an additional 249,838 shares in the last quarter. Finally, SG Americas Securities LLC boosted its stake in shares of Organogenesis by 39.8% during the 1st quarter. SG Americas Securities LLC now owns 790,766 shares of the company’s stock worth $1,874,000 after acquiring an additional 225,265 shares in the last quarter. Hedge funds and other institutional investors own 49.57% of the company’s stock.

About Organogenesis

Organogenesis Holdings Inc is a biotechnology company focused on regenerative medicine products for wound care, surgical procedures and sports medicine. The company develops and commercializes biologically derived products designed to support tissue repair and healing.

Its advanced wound care portfolio includes Apligraf, a living cellular skin substitute used in the treatment of certain chronic wounds, as well as products such as Dermagraft, Affinity, NuShield and other wound coverings and tissue matrices.